Generic launch was impossible, says Impax
Impax has argued in court that although it had bottled $1.5 million worth of Oxymorphone by June 2010, it wasn’t prepared to launch at risk because the company hadn’t made enough of the drug to last a month in the market.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10